Clinical trials: Treatment Resistant Hypertension
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Hypertension, Resistant to Conventional Therapy
RADIANCE Continued Access Protocol
RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects…
- Conditions
- Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE CAP (NCT05017935)
- Testing
- Renal Denervation
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- ReCor Medical, Inc.
Treatment Resistant Hypertension
Protocol for a Multicentre Survey of Patients With Treatment Resistant Hypertension
Project aims to determine the number of individuals with treatment resistant hypertension and to define the characteristics of these patients and estimate disease frequency.
- Trial name
- SPIRIT (NCT03078244)
- Testing
- N/A, observational study
- Volunteers
- 1,500 people
- Sponsor
- Emerald Clinical Inc.
Hypertension
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor…
- Trial name
- Darusentan (NCT00389675)
- Testing
- Darusentan, Guanfacine
- Where
- 99 sites in United States, Argentina and 2 more
- Volunteers
- 661 people
- Sponsor
- Gilead Sciences
Hypertension Resistant to Conventional Therapy
A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension
The ReDy™ System (Renal Dynamics) is a renal denervation device incorporating a variety of ablation features and technical improvements over previously designed systems into a single product.
- Trial name
- NCT02690909
- Testing
- Redy™ Renal Denervation System
- Where
- 10 sites in Belgium, Germany and 6 more
- Volunteers
- 55 people
- Sponsor
- Renal Dynamics GmbH
Hypertension
Carotid Body Removal for the Treatment of Resistant Hypertension
This is a pilot study to assess the effectiveness, safety and feasibility of carotid body removal in patients with high blood pressure (hypertension) resistant to medical treatment.
- Trial name
- NCT01745172
- Testing
- Carotid body excision
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- Noblewell
Resistant Hypertension
A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension
HQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3…
- Trial name
- NCT06216808
- Testing
- HyperQure Renal Denervation System
- Where
- 7 sites in South Korea
- Volunteers
- 10 people
- Sponsor
- DeepQure Inc.
Hypertension
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00364026
- Testing
- darusentan
- Sponsor
- Gilead Sciences
Hypertension
Firibastat in Treatment-resistant Hypertension
This is a double-blind, placebo-controlled, multicenter, efficacy and safety study of firibastat (QGC001) administered po bid over 12 weeks in male and female subjects ≥18 years of age at Screening, with uncontrolled primary HTN.
- Trial name
- FRESH (NCT04277884)
- Testing
- Firibastat
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 515 people
- Sponsor
- Quantum Genomics SA
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Inflammation, Hypertension
Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.
The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on low grade inflammation and vascular function in hypertensive patients.
- Trial name
- NCT00770497
- Testing
- Pioglitazone, Pioglitazone and ramipril, Ramipril
- Where
- 13 sites in Germany
- Volunteers
- 172 people
- Sponsor
- Takeda
Hypertension, Metabolic Syndrome
Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension
The objective of the study is to evaluate the safety of renal denervation using the iRF System and to understand any potential improvement in hypertension.
- Trial name
- RADAR (NCT04740723)
- Testing
- iRF System Renal Denervation
- Where
- 2 sites in Georgia
- Volunteers
- 30 people
- Sponsor
- Metavention
Hypertension, Resistant to Conventional Therapy
Baroloop Multicenter Trial (Baroloop MCT)
The goal of this clinical trial is to learn weather the baroloop system is safe and works to treat hypertension in adults that do not respond sufficiently to medication.
- Trial name
- NCT06518915
- Testing
- baroloop system
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 3 people
- Sponsor
- neuroloop GmbH
Hypertension, Resistant to Conventional Therapy
Addition of Homeopathy in Patients With Resistant Arterial Hypertension
Resistant hypertension (RHTN) is a common clinical problem faced by both primary care clinicians and specialists worldwide. Patients with RHTN have higher rates of cardiovascular events and mortality compared with patients with…
- Trial name
- NCT02124473
- Testing
- Homeopathy
- Where
- 2 sites in India
- Volunteers
- 79 people
- Sponsor
- Macmillan Research Group UK
Hypertension
Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals
Study Objectives The study is to identify prevalence, demography and clinical characteristics of patients with resistant hypertension among hypertensive patients who have been treated in general hospitals in Korea from Jan 2012…
- Trial name
- Teveten_RH (NCT01753206)
- Where
- South Korea
- Volunteers
- 1,579 people
- Sponsor
- Handok Inc.
Hypertension, Resistant to Conventional Therapy
Continued Safety and Performance of the TIVUS System
The TIVUS II is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System consisting of three (3) concurrent cohorts: TIVUS™ Severe Resistant HTN Cohort TIVUS™…
- Trial name
- NCT01835535
- Testing
- TIVUS
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- Cardiosonic
Hypertension,Essential
First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension
The carotid body is located at the bifurcation of the internal and external carotid arteries. It is a chemoreceptor that plays a role in the sympathetic nervous system and in the development and maintenance of hypertension.
- Trial name
- NCT03314012
- Testing
- Catheter-Based Carotid Body Ablation
- Where
- 7 sites in Australia, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Cibiem, Inc.